Morningstar9d
New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference
1,2,3 Thymidine kinase 2 deficiency is an ultra-rare, life-threatening, genetic mitochondrial disease characterized by progressive and severe muscle weakness (myopathy), which can impact the ...
The Pharma Letter9d
UCB presents new data on thymidine kinase 2 deficiency treatment
Belgium’s largest drugmaker UCB (Euronext: UCB) today announced positive data from studies involving its investigational ...
PharmiWeb9d
New data on investigational therapy for thymidine…
UCB, a global biopharmaceutical company, today announced positive data from studies involving its investigational pyrimidine nucleoside therapy, doxecitine (dC) and doxribtimine (dT), in people living ...
UCB annonce des résultats positifs d'études portant sur son traitement expérimental, la doxécitine et la doxribtimine
UCB a annoncé des données positives issues d'études portant sur son traitement expérimental à base de nucléosides ...
Le Moniteur des pharmacies3d
Lonsurf : sa prise en charge est étendue
Le Journal officiel du 25 mars 2025 annonce l’extension de la prise en charge de l'anticancéreux Lonsurf (trifluridine et tipiracil).
New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference
UCB, a global biopharmaceutical company, today announced positive data from studies involving its investigational pyrimidine nucleoside therapy, doxecitine (dC) and doxribtimine (dT), in people living ...